创新医疗管理股份有限公司 关于诉讼事项的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 创新医疗管理股份有限公司（以下简称"公司"）于2025年4月4日披露了韩 猛以公司未办理相关股份的解除限售手续为案由，起诉公司及公司董事的相关诉 讼公告（具体情况详见公司披露于《证券时报》、《上海证券报》、《证券日报》、 《中国证券报》以及巨潮资讯网(http://www.cninfo.com.cn)的相关公告，公告 编号：2025-011）。近日，公司收到上海市浦东新区人民法院关于上述案件的《民 事判决书》（（2025）沪0115民初26824号）。现将有关情况公告如下： 一、本次收到《民事判决书》判决情况 公司于近日收到上海市浦东新区人民法院《民事判决书》（（2025）沪0115 民初26824号），上海市浦东新区人民法院对上述案件作出判决，判决如下： （一）被告创新医疗管理股份有限公司应于本判决生效之日起十日内为原告 韩猛所持被告创新医疗管理股份有限公司共计4,275,513股限售股办理解除限售 手续； （二）驳回原告韩猛的其余诉讼请求。 案件受理费 193 ...

近5日资金流向一览见下表： 9月19日的资金流向数据方面，主力资金净流出1.43亿元，占总成交额12.35%，游资资金净流出5144.13 万元，占总成交额4.43%，散户资金净流入1.95亿元，占总成交额16.78%。 | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-19 | 22.47 -4.30% | | -1.43 Z | -12.35% | -5144.13万 | -4.43% | 1.954Z | - 16.78% | | 2025-09-18 | 23.48 -4.75% | | -3.18亿 | -14.70% | -3164.17万 | -1.46% | 3.50亿 | 16.17% | | 2025-09-17 | 24.65 | -1.48% | -9354.87万 | -6.05% | 5054.48万 | 3.27% | 4300.39万 | 2.78% | | 2025-09-1 ...

Market Overview - On September 18, the medical services sector declined by 1.68%, with Nanmo Biology leading the drop [1] - The Shanghai Composite Index closed at 3831.66, down 1.15%, while the Shenzhen Component Index closed at 13075.66, down 1.06% [1] Stock Performance - Notable gainers included: - Zenggansi (301257) with a closing price of 53.80, up 6.89% [1] - Yangguang Nuohuo (688621) at 79.58, up 1.38% [1] - Kanglong Huacheng (300759) at 35.70, up 0.59% [1] - Major decliners included: - Nanmo Biology (688265) at 56.16, down 5.93% [2] - Chuangxin Medical (002173) at 23.48, down 4.75% [2] - Hongbo Pharmaceutical (301230) at 36.12, down 4.06% [2] Capital Flow - The medical services sector experienced a net outflow of 2.099 billion yuan from institutional investors, while retail investors saw a net inflow of 1.474 billion yuan [2] - The sector's overall capital flow indicates a mixed sentiment among different investor types [2] Individual Stock Capital Flow - Notable capital flows included: - Huada Gene (300676) with a net inflow of 63.2761 million yuan from institutional investors [3] - Baicheng Pharmaceutical (301096) with a net inflow of 21.5534 million yuan from institutional investors [3] - Nanmo Biology (688265) saw a net outflow of 1.597 million yuan from institutional investors [3]

该股主要指标及行业内排名如下： 证券之星消息，截至2025年9月17日收盘，创新医疗(002173)报收于24.65元，下跌1.48%，换手率 15.02%，成交量62.53万手，成交额15.47亿元。 9月17日的资金流向数据方面，主力资金净流出9354.87万元，占总成交额6.05%，游资资金净流入 5054.48万元，占总成交额3.27%，散户资金净流入4300.39万元，占总成交额2.78%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-17 | 24.65 | -1.48% | -9354.87万 | -6.05% | 5054.48万 | 3.27% | 4300.39万 | 2.78% | | 2025-09-16 | 25.02 | 2.63% | 8871.86万 | 4.19% | -573.72万 | -0.27% | -8298.15万 | -3.92 ...

Group 1 - The first brain-computer interface (BCI) industry standard in China has been officially released, which will take effect on January 1, 2026, laying the foundation for the high-quality development of the BCI medical device industry [2] - The standard defines the terminology and definitions related to medical devices that utilize BCI technology, marking a significant step in the establishment of a regulatory framework for the industry [2] - The Chinese government aims to achieve breakthroughs in key BCI technologies by 2027, establishing an advanced technical, industrial, and standard system, with the goal of creating 2 to 3 industrial clusters and expanding new applications and business models [2] Group 2 - A-share BCI concept stocks have seen an average increase of 62.55% this year, with companies like Hanwei Technology, Innovation Medical, Sino Medical, and Rongtai Health experiencing stock price increases exceeding 170% [2] - Seven companies have received institutional research since September, with Xiangyu Medical receiving the most attention from 49 institutions, focusing on self-developed core components for BCI applications [3] - Dao's Technology has invested in leading BCI companies to enhance its capabilities in medical rehabilitation and human-computer interaction, indicating a trend of collaboration within the industry [3] Group 3 - Market funds have been actively increasing their positions in BCI concept stocks, with half of these stocks receiving net purchases from financing clients since September, and several stocks seeing net purchases exceeding 100 million yuan [4] - Notable companies with significant net purchases include Sanqi Interactive Entertainment, Dao's Technology, and Hanwei Technology, reflecting strong market interest in the BCI sector [4]

Core Viewpoint - Innovation Medical (002173) reported a closing price of 24.38 yuan on September 15, 2025, with a 1.58% increase, indicating a positive market response despite mixed fund flows [1] Group 1: Stock Performance and Fund Flows - On September 15, 2025, the stock had a turnover rate of 16.27%, with a trading volume of 677,500 hands and a transaction amount of 1.652 billion yuan [1] - The net outflow of main funds was 17.4485 million yuan, accounting for 1.06% of the total transaction amount, while the net inflow of speculative funds was 24.0722 million yuan, representing 1.46% of the total [1][2] - Retail investors experienced a net outflow of 6.6237 million yuan, which is 0.4% of the total transaction amount [1][2] Group 2: Recent Financial Performance - For the first half of 2025, Innovation Medical reported a main revenue of 402 million yuan, a year-on-year decrease of 1.6%, while the net profit attributable to shareholders was -11.3613 million yuan, an increase of 29.12% year-on-year [3] - The second quarter of 2025 saw a single-quarter main revenue of 208 million yuan, a year-on-year increase of 0.73%, and a net profit attributable to shareholders of 2.5761 million yuan, up 119.74% year-on-year [3] - The company’s gross profit margin stood at 12.06%, significantly lower than the industry average of 35.92% [3] Group 3: Company Metrics and Industry Comparison - Innovation Medical's total market value is 10.759 billion yuan, compared to the industry average of 21.569 billion yuan, ranking 15th out of 42 in the medical services sector [3] - The company has a negative price-to-earnings ratio of -473.47, while the industry average is 85.14, indicating significant underperformance [3] - The debt ratio is reported at 18.03%, with investment income of -2.5952 million yuan and financial expenses of 3.603 million yuan [3]

Group 1 - The core viewpoint of the articles highlights the advancements in healthcare services and the implementation of innovative medical practices in Nantong, focusing on improving elderly care and integrating technology into healthcare [1][2][3][4][5][6][7] Group 2 - Nantong has launched the "Disability and Dementia Prevention Intervention Course," which has expanded from 4 to 18 communities, benefiting over 500 elderly individuals [1] - The city has established a local standard for elderly disability and dementia intervention, marking a significant step in enhancing healthcare for the aging population [1] - The "Five Integrations" approach in Nantong's medical innovation aims to enhance healthcare resources by merging various sectors, including basic research, clinical innovation, and industry collaboration [2] - The establishment of a regional demonstration medical innovation platform is expected to improve healthcare quality and accessibility [2] - The introduction of an AI diagnostic platform has significantly reduced the time for detecting bone density issues, showcasing the integration of technology in clinical settings [3] - Nantong's digital regulatory platform has improved oversight of healthcare institutions, generating over 124,000 prescription warnings and ensuring timely responses to potential issues [4] - The city has implemented a "Cardiac Network" in grassroots healthcare, equipping community health service stations with portable ECG devices to enhance emergency response capabilities [5] - Nantong's collaboration with grassroots health centers to create a "shared Chinese medicine pharmacy" has improved access to traditional medicine for over 1,500 residents [6] - The city is exploring the establishment of nursing homes in primary healthcare institutions to meet the growing demand for integrated medical and nursing services [7] - Nantong aims to create a healthcare service system that is more reliable, effective, and satisfactory for the public, with a focus on enhancing the quality of medical facilities [7]

Core Insights - China's innovative biopharmaceuticals have gained global attention, with over $66 billion in licensing deals in the first half of the year, showcasing a significant moment for Chinese biomedicine [1] - The innovative medical device sector in China has not yet reached a similar level of global recognition, raising questions about whether the success of innovative drugs can be replicated in medical devices [1] Group 1: Development of Innovative Medical Devices - The Chinese cardiovascular medical device sector has historically relied on imports, leading to high costs, but there is now a push for affordable, innovative solutions [2] - The establishment of the CCI medical innovation platform has led to the incubation of over 50 innovative medical devices and the filing of more than 1,000 patents [2] - Despite the approval of 269 innovative medical devices during the "14th Five-Year Plan" period, the global intellectual property (IP) presence of these devices remains limited compared to innovative drugs [3] Group 2: Challenges in Global Market Recognition - The late start of China's innovative medical devices and a reliance on imitation rather than original thinking pose significant challenges for global market acceptance [3] - The innovation ecosystem for medical devices in China is still maturing, with a need for improved capital and commercialization capabilities [3] - Early-stage licensing deals for medical devices often do not attract high valuations, contrasting sharply with the multi-billion dollar deals seen in innovative pharmaceuticals [3] Group 3: Barriers to Innovation and Licensing - The path to innovation in medical devices differs significantly from pharmaceuticals, with small innovations often facing intellectual property challenges [4] - High costs associated with clinical registration and certification hinder the ability of Chinese medical devices to attract international partnerships [4] - The prevalence of similar products in the market leads to intense price competition, making it difficult for truly innovative products to stand out [4][5] Group 4: Future Outlook - There is optimism that as more original medical technologies emerge from China, the potential for globally recognized products will increase [5] - The manufacturing advantages of China could play a crucial role in the future success of its innovative medical devices on the global stage [5] - The industry must differentiate between genuine innovation and superficial changes to foster a thriving environment for medical device innovation [5]

Core Insights - China's innovative medical devices face significant challenges in gaining global market recognition, unlike the successful international licensing of innovative drugs [1][3] - The development of innovative medical devices in China is still in its early stages, primarily relying on imitation rather than original innovation [3][4] - The innovation ecosystem for medical devices in China is not yet mature, with a need for improved capital and commercialization capabilities [3][4] Group 1: Current State of Innovation - In the first half of the year, China's innovative biopharmaceuticals attracted global attention with licensing deals amounting to nearly $66 billion [1] - The Chinese cardiovascular intervention medical devices have historically depended on imports, leading to high costs, but there is a growing push for affordable domestic alternatives [2] - The number of approved innovative medical devices (269) during the 14th Five-Year Plan period is comparable to that of innovative drugs (210) [3] Group 2: Challenges in Global Market Entry - The path to international licensing for innovative medical devices differs significantly from that of drugs, with many devices facing high costs and regulatory hurdles [4][5] - The lack of original innovative products leads to severe homogenization in the market, making it difficult for truly innovative products to compete [5] - Cross-border giants are hesitant to license early-stage medical devices unless there is a clear expectation of regulatory approval, which is a costly process for domestic innovators [4][5] Group 3: Future Outlook - Despite current challenges, there is optimism that China's innovative medical devices will eventually gain global traction as more original technologies emerge [5] - The potential for global first-in-class products exists, similar to advancements seen in antibody-drug conjugates and bispecific antibodies [5] - The industry must differentiate between genuine innovation and superficial changes to foster a thriving environment for medical device innovation in China [5]

Core Viewpoint - The pharmaceutical sector in the A-share market has shown structural performance, with the innovative drug index rising by 60.77% year-to-date, significantly outperforming the overall A-share index by 22.14% [1] Group 1: Pharmaceutical Sector Performance - The pharmaceutical sector has been active this year, with innovative drug indices leading the gains [1] - The performance of pharmaceutical-themed mutual funds has attracted investor attention, with notable returns reported [1] - Zhongyin Fund's pharmaceutical-themed funds have ranked well among peers, with Zhongyin Innovation Medical A achieving top rankings over various time frames [1] Group 2: Fund Manager Insights - Fund manager Zheng Ning employs a long-term pricing focus, filtering out market noise to concentrate on long-term implied returns [3] - The performance of Zhongyin Hong Kong Stock Connect Pharmaceutical A has shown significant growth, with a net value growth rate of 70.08% in the first half of 2025 [3] - Zheng Ning has managed multiple funds, consistently achieving competitive returns compared to benchmarks [4][6] Group 3: Market Drivers - The recent rise in the innovative drug sector is driven by fundamental improvements, including advancements in R&D, successful profit realization, and favorable policies [2] - The innovative drug industry is expected to have substantial growth potential, becoming a strategic industry in China's export structure and a key pillar in the global pharmaceutical industry [2]